Distalmotion Marks First Multi-Robot Sale in the U.S. with DEXTER® Surgical System at AdventHealth

Image Courtesy: Public Domain

Distalmotion, a global MedTech company advancing access to robotic surgery, has reached a key milestone in its US expansion with the first multi-robot sale in the country. AdventHealth, which operates 50 hospitals in nine states, has selected the DEXTER® Robotic Surgery System to support the growth of minimally invasive surgery in its outpatient department and has already completed its first cases with the system.

“We’re excited to have completed our first cases with DEXTER as we bring robotic surgery to our outpatient department. As we expand our capabilities, we’re focused on solutions that align with our goals for flexibility and efficiency,” said Dr. Carlos Ortiz-Ortiz MD, FACS, General Surgeon at AdventHealth Celebration.

As demand for surgical robotics continues to rise and more high-volume soft tissue procedures—such as inguinal hernia repair and cholecystectomy—move into outpatient settings, healthcare facilities are seeking solutions that match their clinical and operational needs. However, their focus on efficiency and patient experience makes existing soft tissue robots impractical due to size, operational complexity, and costs.

DEXTER is purpose-built for this shift. Its small format and mobile design allow it to integrate into any operating room and be easily maneuvered between rooms—helping reduce turnover time and maximize throughput. It is the only system available in the US and European markets with both a sterile console and fully open architecture. The sterile console enables flexible workflows by allowing surgeons to perform bedside tasks and then immediately return to robotic operation without a change in sterility or redocking of the robot. Its open architecture supports the use of preferred instruments and OR technologies that are already available in the facility, minimizing supply chain burden to purchase a new suite of costly robotic technologies and maximizing value. Together, these features give surgeons full control to perform procedures in the way they believe is best for each patient.

“This multi-system sale underscores how health systems are seeking more flexible solutions that bring the benefits of robotics to ORs across their sites of care,” said Greg Roche, CEO of Distalmotion. “DEXTER is designed to meet the realities of outpatient surgery, without compromising existing practices.”

This milestone builds on Distalmotion’s growing footprint in the US and Europe, with more than 2,000 procedures completed globally across general, gynecological, and urological specialties. The company remains focused on making robotic surgery more accessible across more sites of care globally.

Note: The DEXTER Robotic Surgery System is currently authorized for use in adult inguinal hernia repair and cholecystectomy in the United States.